Atsena Therapeutics: Funding, Investors & Team (Sep 2026)
Atsena Therapeutics is a company in the advanced stages of testing genetic therapy that aims to reverse or stop vision loss. They are currently conducting a clinical trial for a potential treatment targeting a common cause of childhood blindness. Atsena's research and development pipeline utilizes adeno-associated virus technology, which is designed to address the challenges associated with inherited retinal diseases. The company's approach is individualized to meet the unique requirements of each patient's condition.
Atsena Therapeutics has raised $175M across 2 funding rounds on record, the most recent a Series C of $150M announced in Apr 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atsena Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2025.
Atsena Therapeutics Funding Rounds
Atsena Therapeutics raised $24.5M in an undisclosed round announced in Oct 2023.
1.5 years later, a Series C of $150M was announced in Apr 2025.
Atsena Therapeutics Founders and Leadership Team
Contact details for the Atsena Therapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Atsena Therapeutics Funding Compared to Other Biotechnology Startups
Atsena Therapeutics' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atsena Therapeutics in Biotechnology and Durham
Companies Similar to Atsena Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Atsena Therapeutics Funding FAQs
What does Atsena Therapeutics do?
Atsena Therapeutics is a company in the advanced stages of testing genetic therapy that aims to reverse or stop vision loss. They are currently conducting a clinical trial for a potential treatment targeting a common cause of childhood blindness. Atsena's research and development pipeline utilizes adeno-associated virus technology, which is designed to address the challenges associated with inherited retinal diseases. The company's approach is individualized to meet the unique requirements of each patient's condition.
How much funding has Atsena Therapeutics raised?
Atsena Therapeutics has raised $175M across 2 rounds on record. The most recent is a Series C of $150M announced in Apr 2025.
When did Atsena Therapeutics last raise funding?
Atsena Therapeutics' most recent funding round on record is a Series C of $150M, announced in Apr 2025.
Who founded Atsena Therapeutics?
FundedIQ lists Sanford Boye (Founder), Shannon Boye (Founder) at Atsena Therapeutics.
Where is Atsena Therapeutics headquartered?
Atsena Therapeutics is based in Durham, North Carolina, United States.
How many employees does Atsena Therapeutics have?
Atsena Therapeutics is in the 11-50 employee band.
How does Atsena Therapeutics' funding compare to other Biotechnology startups?
Atsena Therapeutics' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Atsena Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atsena Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.